Clinical Trial Update: A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation and confirmation study of PT-112 combined with avelumab was conducted in advanced solid tumors, including non-small cell lung cancer, across P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avelumab (avelumab)
• PT-112

Snippet

Sponsor: Promontory Therapeutics Inc. | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Phase 1, Phase 2 | Status: COMPLETED